arrow_back Back to App

Expanding Incentives for Valley Fever Drug Development.

This bill expands the Priority Review Voucher program to include Coccidioidomycosis (Valley Fever), a fungal infection. By adding this disease, the law aims to incentivize pharmaceutical companies to accelerate the development of new treatments and preventive measures. This change could lead to faster availability of effective therapies for citizens affected by this often-neglected condition.
Key points
Coccidioidomycosis (Valley Fever) is added to the list of diseases eligible for the Priority Review Voucher program.
The goal is to encourage pharmaceutical companies to develop treatments and prevention methods for this fungal infection more quickly.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_3220
Sponsor: Sen. Kelly, Mark [D-AZ]
Process start date: 2023-11-02
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_3220.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-11-02.

What are the main provisions?

Key points include:

  • Coccidioidomycosis (Valley Fever) is added to the list of diseases eligible for the Priority Review Voucher program.
  • The goal is to encourage pharmaceutical companies to develop treatments and prevention methods for this fungal infection more quickly.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Kelly, Mark [D-AZ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health